Grufity logo
Grufity logo
AVTX

AVTX - Avalo Therapeutics, Inc. Stock Price, Fair Value and News

$19.52+0.02 (+0.10%)
Market Closed as of 28 Jul 2026, 04:00 pm ET

14/100

AVTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

14/100

AVTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

AVTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AVTX Price Action

Last 7 days

3.7%

Last 30 days

7.2%

Last 90 days

47.9%

Trailing 12 Months

196.7%

AVTX RSI Chart

AVTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AVTX Valuation

Market Cap

1.0B

Price/Earnings (Trailing)

-12.11

Price/Sales (Trailing)

17.3K

EV/EBITDA

-11.87

Price/Free Cashflow

-17.17

AVTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

AVTX Fundamentals

AVTX Revenue

Revenue (TTM)

59.0K

AVTX Earnings

Earnings (TTM)

-84.7M

Earnings Growth (Yr)

-49.29%

Earnings Growth (Qtr)

-43.08%

AVTX Profitability

EBT Margin

-143340.68%

Return on Equity

-124.03%

Return on Assets

-84.84%

Free Cashflow Yield

-5.82%

AVTX Investor Care

Shares Dilution (1Y)

399.92%

Diluted EPS (TTM)

-5.51

Revenue & Growth

How Avalo Therapeutics, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2025---59.0K
2024--1.7M1.2M
202314.0M10.0M6.0M1.9M
20226.1M3.8M17.4M18.1M
20214.4M6.4M6.7M5.4M
20206.9M6.9M5.8M6.7M
20197.0M6.9M6.8M6.8M
201832.2M36.5M15.6M7.0M
20171.5M10.3M19.1M27.8M
2016---1.2M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Avalo Therapeutics, Inc.

AVTX
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
 CEO
 WEBSITEavalotx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES20

Avalo Therapeutics, Inc. Frequently Asked Questions

AVTX is the stock ticker symbol of Avalo Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jul 28 2026, market cap of Avalo Therapeutics, Inc. is 1.03 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Tue Jul 28 2026, AVTX's PE ratio (Price to Earnings) is -12.11 and Price to Sales (PS) ratio is 17.27 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVTX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Avalo Therapeutics, Inc. has provided -0.469 (multiply by 100 for percentage) rate of return.